Beam Therapeutics Inc. Lease, Cost
Beam Therapeutics Inc. (BEAM) reported Lease, Cost of $32.51 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-24
- Beam Therapeutics Inc. lease, cost for the quarter ending 2022-12-31 was $6.10M, a 4.74% increase year-over-year.
- Beam Therapeutics Inc. lease, cost for the quarter ending 2022-09-30 was $5.66M, a 2.32% increase year-over-year.
- Beam Therapeutics Inc. lease, cost for the quarter ending 2022-06-30 was $5.71M, a 7.94% increase year-over-year.
- Beam Therapeutics Inc. lease, cost for the quarter ending 2022-03-31 was $5.42M, a 13.74% increase year-over-year.
- Beam Therapeutics Inc. lease, cost for fiscal 2025 was $32.51M, a 12.00% decline from fiscal 2024.
- Beam Therapeutics Inc. lease, cost for fiscal 2024 was $36.94M, a 0.28% increase from fiscal 2023.
- Beam Therapeutics Inc. lease, cost for fiscal 2023 was $36.84M, a 60.96% increase from fiscal 2022.
- Beam Therapeutics Inc. lease, cost for fiscal 2022 was $22.89M, a 6.91% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 9 month as first filed | Lease, Cost 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $32.51M 10-K · filed 2026-02-24 | ||||
| 2024-12-31 | $36.94M 10-K · filed 2026-02-24 | ||||
| 2023-12-31 | $36.84M 10-K · filed 2026-02-24 | ||||
| 2022-12-31 | $6.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $11.76M derived: sum of 2 quarters · filed 2025-02-25 | $17.46M derived: sum of 3 quarters · filed 2025-02-25 | $22.89M 10-K · filed 2025-02-25 | |
| 2022-09-30 | $5.66M 10-Q · filed 2022-11-07 | $11.36M derived: sum of 2 quarters · filed 2022-11-07 | $16.79M 10-Q · filed 2022-11-07 | $22.61M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-06-30 | $5.71M 10-Q · filed 2022-08-09 | $11.13M 10-Q · filed 2022-08-09 | $16.96M derived: sum of 3 quarters · filed 2024-02-27 | $22.48M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2022-03-31 | $5.42M 10-Q · filed 2022-05-09 | $11.25M derived: sum of 2 quarters · filed 2024-02-27 | $16.78M derived: sum of 3 quarters · filed 2024-02-27 | $22.06M derived: sum of 4 quarters · filed 2024-02-27 | |
| 2021-12-31 | $5.83M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $11.35M derived: sum of 2 quarters · filed 2024-02-27 | $16.64M derived: sum of 3 quarters · filed 2024-02-27 | $21.41M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $5.53M 10-Q · filed 2022-11-07 | $10.81M derived: sum of 2 quarters · filed 2022-11-07 | $15.58M 10-Q · filed 2022-11-07 | $19.20M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $5.29M 10-Q · filed 2022-08-09 | $10.05M 10-Q · filed 2022-08-09 | $13.67M derived: sum of 3 quarters · filed 2023-02-28 | $15.56M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $4.77M 10-Q · filed 2022-05-09 | $8.38M derived: sum of 2 quarters · filed 2023-02-28 | $10.27M derived: sum of 3 quarters · filed 2023-02-28 | $12.23M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $3.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $5.50M derived: sum of 2 quarters · filed 2023-02-28 | $7.46M derived: sum of 3 quarters · filed 2023-02-28 | $9.34M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.89M 10-Q · filed 2021-11-08 | $3.85M derived: sum of 2 quarters · filed 2021-11-08 | $5.73M 10-Q · filed 2021-11-08 | $5.73M 10-Q · filed 2020-11-10 | $7.55M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $1.95M 10-Q · filed 2021-08-10 | $3.84M 10-Q · filed 2021-08-10 | $5.65M derived: sum of 3 quarters · filed 2022-02-28 | $6.80M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2020-03-31 | $1.89M 10-Q · filed 2021-05-11 | $3.70M derived: sum of 2 quarters · filed 2022-02-28 | $4.84M derived: sum of 3 quarters · filed 2022-02-28 | $5.93M derived: sum of 4 quarters · filed 2022-02-28 | |
| 2019-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $2.96M derived: sum of 2 quarters · filed 2022-02-28 | $4.05M derived: sum of 3 quarters · filed 2022-02-28 | $4.95M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $1.15M 10-Q · filed 2020-11-10 | $2.23M derived: sum of 2 quarters · filed 2020-11-10 | $3.14M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | $1.09M 10-Q · filed 2020-08-12 | $2.00M 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $908.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |